Annual FCF
-$124.69 M
+$92.50 M+42.59%
31 December 2023
Summary:
Inovio Pharmaceuticals annual free cash flow is currently -$124.69 million, with the most recent change of +$92.50 million (+42.59%) on 31 December 2023. During the last 3 years, it has risen by +$54.81 million (+30.54%). INO annual FCF is now -4340.40% below its all-time high of -$2.81 million, reached on 31 December 2003.INO Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$27.44 M
+$1.22 M+4.25%
30 September 2024
Summary:
Inovio Pharmaceuticals quarterly free cash flow is currently -$27.44 million, with the most recent change of +$1.22 million (+4.25%) on 30 September 2024. Over the past year, it has increased by +$1.67 million (+5.73%). INO quarterly FCF is now -287.42% below its all-time high of $14.64 million, reached on 30 September 2015.INO Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$111.18 M
+$1.67 M+1.48%
30 September 2024
Summary:
Inovio Pharmaceuticals TTM free cash flow is currently -$111.18 million, with the most recent change of +$1.67 million (+1.48%) on 30 September 2024. Over the past year, it has increased by +$23.74 million (+17.60%). INO TTM FCF is now -4384.36% below its all-time high of -$2.48 million, reached on 30 June 2003.INO TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INO Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +42.6% | +5.7% | +17.6% |
| 3 y3 years | +30.5% | +41.2% | +51.8% |
| 5 y5 years | -64.8% | +1.5% | -8.3% |
INO Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +42.6% | -4.4% | +59.4% | at high | +51.8% |
| 5 y | 5 years | -64.8% | +42.6% | -98.1% | +65.1% | -21.8% | +57.0% |
| alltime | all time | -4340.4% | +42.6% | -287.4% | +65.1% | -4384.4% | +57.0% |
Inovio Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$27.44 M(-4.3%) | -$111.18 M(-1.5%) |
| June 2024 | - | -$28.66 M(-0.5%) | -$112.84 M(-3.2%) |
| Mar 2024 | - | -$28.80 M(+9.6%) | -$116.52 M(-6.5%) |
| Dec 2023 | -$124.69 M(-42.6%) | -$26.28 M(-9.7%) | -$124.69 M(-7.6%) |
| Sept 2023 | - | -$29.11 M(-10.0%) | -$134.92 M(-22.2%) |
| June 2023 | - | -$32.34 M(-12.5%) | -$173.36 M(-9.8%) |
| Mar 2023 | - | -$36.96 M(+1.3%) | -$192.26 M(-11.5%) |
| Dec 2022 | -$217.18 M(+0.1%) | -$36.51 M(-46.0%) | -$217.18 M(-0.9%) |
| Sept 2022 | - | -$67.55 M(+31.8%) | -$219.21 M(+10.5%) |
| June 2022 | - | -$51.25 M(-17.2%) | -$198.32 M(-12.1%) |
| Mar 2022 | - | -$61.88 M(+60.6%) | -$225.74 M(+4.1%) |
| Dec 2021 | -$216.94 M(+20.9%) | -$38.53 M(-17.4%) | -$216.94 M(-5.9%) |
| Sept 2021 | - | -$46.66 M(-40.7%) | -$230.58 M(-10.8%) |
| June 2021 | - | -$78.67 M(+48.2%) | -$258.46 M(+24.9%) |
| Mar 2021 | - | -$53.08 M(+1.7%) | -$206.98 M(+15.3%) |
| Dec 2020 | -$179.50 M(+81.6%) | -$52.18 M(-30.0%) | -$179.50 M(+27.1%) |
| Sept 2020 | - | -$74.54 M(+174.2%) | -$141.17 M(+49.4%) |
| June 2020 | - | -$27.19 M(+6.2%) | -$94.50 M(+3.5%) |
| Mar 2020 | - | -$25.59 M(+84.8%) | -$91.32 M(-7.6%) |
| Dec 2019 | -$98.84 M(+30.7%) | -$13.85 M(-50.3%) | -$98.84 M(-3.7%) |
| Sept 2019 | - | -$27.87 M(+16.1%) | -$102.61 M(+3.1%) |
| June 2019 | - | -$24.01 M(-27.5%) | -$99.54 M(+4.8%) |
| Mar 2019 | - | -$33.11 M(+87.9%) | -$95.02 M(+25.6%) |
| Dec 2018 | -$75.64 M(+2.9%) | -$17.62 M(-28.9%) | -$75.64 M(+3.8%) |
| Sept 2018 | - | -$24.80 M(+27.3%) | -$72.84 M(+5.7%) |
| June 2018 | - | -$19.48 M(+41.9%) | -$68.94 M(-3.2%) |
| Mar 2018 | - | -$13.73 M(-7.4%) | -$71.21 M(-3.1%) |
| Dec 2017 | -$73.50 M(+10.5%) | -$14.83 M(-29.1%) | -$73.50 M(-0.2%) |
| Sept 2017 | - | -$20.90 M(-3.9%) | -$73.65 M(+2.5%) |
| June 2017 | - | -$21.76 M(+35.8%) | -$71.86 M(+8.7%) |
| Mar 2017 | - | -$16.02 M(+7.0%) | -$66.09 M(-0.6%) |
| Dec 2016 | -$66.49 M(+336.9%) | -$14.97 M(-21.7%) | -$66.49 M(+12.5%) |
| Sept 2016 | - | -$19.12 M(+19.6%) | -$59.12 M(+133.1%) |
| June 2016 | - | -$15.99 M(-2.7%) | -$25.36 M(+33.2%) |
| Mar 2016 | - | -$16.42 M(+116.1%) | -$19.05 M(+25.1%) |
| Dec 2015 | -$15.22 M(-51.2%) | -$7.60 M(-151.9%) | -$15.22 M(-4.1%) |
| Sept 2015 | - | $14.64 M(-251.5%) | -$15.87 M(-59.2%) |
| June 2015 | - | -$9.67 M(-23.2%) | -$38.87 M(+2.1%) |
| Mar 2015 | - | -$12.60 M(+52.7%) | -$38.06 M(+22.0%) |
| Dec 2014 | -$31.20 M(+100.6%) | -$8.25 M(-1.4%) | -$31.20 M(+41.8%) |
| Sept 2014 | - | -$8.36 M(-5.5%) | -$22.01 M(+12.7%) |
| June 2014 | - | -$8.85 M(+54.3%) | -$19.53 M(+21.1%) |
| Mar 2014 | - | -$5.74 M(-705.0%) | -$16.13 M(+3.7%) |
| Dec 2013 | -$15.56 M(-31.0%) | $948.60 K(-116.1%) | -$15.56 M(-29.4%) |
| Sept 2013 | - | -$5.89 M(+8.1%) | -$22.05 M(-0.7%) |
| June 2013 | - | -$5.45 M(+5.4%) | -$22.21 M(+0.1%) |
| Mar 2013 | - | -$5.17 M(-6.7%) | -$22.18 M(-1.6%) |
| Dec 2012 | -$22.55 M(+13.2%) | -$5.54 M(-8.4%) | -$22.55 M(+4.5%) |
| Sept 2012 | - | -$6.05 M(+11.6%) | -$21.59 M(+3.7%) |
| June 2012 | - | -$5.42 M(-2.0%) | -$20.82 M(+4.7%) |
| Mar 2012 | - | -$5.53 M(+20.8%) | -$19.89 M(-0.1%) |
| Dec 2011 | -$19.92 M | -$4.58 M(-13.3%) | -$19.92 M(+6.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | -$5.28 M(+17.7%) | -$18.71 M(+31.5%) |
| June 2011 | - | -$4.49 M(-19.3%) | -$14.23 M(+7.3%) |
| Mar 2011 | - | -$5.56 M(+64.9%) | -$13.27 M(+8.4%) |
| Dec 2010 | -$12.24 M(-14.0%) | -$3.37 M(+317.6%) | -$12.24 M(+8.1%) |
| Sept 2010 | - | -$807.70 K(-77.1%) | -$11.33 M(-23.9%) |
| June 2010 | - | -$3.52 M(-22.4%) | -$14.89 M(-9.4%) |
| Mar 2010 | - | -$4.54 M(+84.6%) | -$16.44 M(+15.4%) |
| Dec 2009 | -$14.25 M(+21.6%) | -$2.46 M(-43.7%) | -$14.25 M(-1.2%) |
| Sept 2009 | - | -$4.37 M(-13.9%) | -$14.42 M(+7.1%) |
| June 2009 | - | -$5.07 M(+115.8%) | -$13.47 M(+16.4%) |
| Mar 2009 | - | -$2.35 M(-10.8%) | -$11.57 M(-1.2%) |
| Dec 2008 | -$11.71 M(-3.7%) | -$2.63 M(-22.8%) | -$11.71 M(+14.6%) |
| Sept 2008 | - | -$3.41 M(+7.4%) | -$10.22 M(+1.9%) |
| June 2008 | - | -$3.18 M(+27.9%) | -$10.03 M(-4.5%) |
| Mar 2008 | - | -$2.49 M(+117.4%) | -$10.50 M(-13.7%) |
| Dec 2007 | -$12.16 M(+44.6%) | -$1.14 M(-64.5%) | -$12.16 M(+23.0%) |
| Sept 2007 | - | -$3.22 M(-11.8%) | -$9.88 M(-0.3%) |
| June 2007 | - | -$3.65 M(-12.0%) | -$9.91 M(+3.2%) |
| Mar 2007 | - | -$4.15 M(-466.6%) | -$9.60 M(+14.2%) |
| Dec 2006 | -$8.41 M(-33.2%) | $1.13 M(-134.8%) | -$8.41 M(-29.9%) |
| Sept 2006 | - | -$3.25 M(-2.7%) | -$12.00 M(+15.2%) |
| June 2006 | - | -$3.34 M(+13.1%) | -$10.42 M(-11.3%) |
| Mar 2006 | - | -$2.95 M(+20.2%) | -$11.74 M(-6.8%) |
| Dec 2005 | -$12.59 M(+82.5%) | -$2.46 M(+47.3%) | -$12.59 M(+0.8%) |
| Sept 2005 | - | -$1.67 M(-64.3%) | -$12.49 M(-3.6%) |
| June 2005 | - | -$4.67 M(+22.8%) | -$12.96 M(+40.3%) |
| Mar 2005 | - | -$3.80 M(+61.4%) | -$9.24 M(+33.8%) |
| Dec 2004 | -$6.90 M(+145.8%) | -$2.36 M(+10.4%) | -$6.90 M(+12.9%) |
| Sept 2004 | - | -$2.13 M(+125.2%) | -$6.12 M(+16.9%) |
| June 2004 | - | -$947.60 K(-35.4%) | -$5.23 M(-4.4%) |
| Mar 2004 | - | -$1.47 M(-6.5%) | -$5.47 M(+94.8%) |
| Dec 2003 | -$2.81 M(-47.7%) | -$1.57 M(+25.6%) | -$2.81 M(+1.0%) |
| Sept 2003 | - | -$1.25 M(+5.1%) | -$2.78 M(+12.1%) |
| June 2003 | - | -$1.19 M(-199.3%) | -$2.48 M(-14.1%) |
| Mar 2003 | - | $1.20 M(-177.8%) | -$2.89 M(-46.3%) |
| Dec 2002 | -$5.37 M(+0.8%) | -$1.54 M(+62.2%) | -$5.37 M(+40.2%) |
| Sept 2002 | - | -$948.70 K(-40.5%) | -$3.83 M(-13.3%) |
| June 2002 | - | -$1.59 M(+24.0%) | -$4.42 M(-16.4%) |
| Mar 2002 | - | -$1.29 M(-16.4%) | -$5.29 M(-36.3%) |
| Dec 2001 | -$5.32 M(-38.3%) | - | - |
| Sept 2001 | - | -$1.54 M(-37.6%) | -$8.29 M(-7.3%) |
| June 2001 | - | -$2.46 M(+4.1%) | -$8.95 M(+3.6%) |
| Mar 2001 | - | -$2.36 M(+22.5%) | -$8.63 M(+2.2%) |
| Mar 2001 | -$8.63 M(-4.9%) | - | - |
| Dec 2000 | - | -$1.93 M(-12.0%) | -$8.45 M(+0.3%) |
| Sept 2000 | - | -$2.19 M(+2.0%) | -$8.42 M(+2.3%) |
| June 2000 | - | -$2.15 M(-1.4%) | -$8.23 M(-9.4%) |
| Mar 2000 | -$9.08 M(+33.5%) | -$2.18 M(+14.7%) | -$9.08 M(+31.6%) |
| Dec 1999 | - | -$1.90 M(-5.0%) | -$6.90 M(+38.0%) |
| Sept 1999 | - | -$2.00 M(-33.3%) | -$5.00 M(+66.7%) |
| June 1999 | - | -$3.00 M | -$3.00 M |
| Mar 1999 | -$6.80 M | - | - |
FAQ
- What is Inovio Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals annual FCF year-on-year change?
- What is Inovio Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals quarterly FCF year-on-year change?
- What is Inovio Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals TTM FCF year-on-year change?
What is Inovio Pharmaceuticals annual free cash flow?
The current annual FCF of INO is -$124.69 M
What is the all time high annual FCF for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high annual free cash flow is -$2.81 M
What is Inovio Pharmaceuticals annual FCF year-on-year change?
Over the past year, INO annual free cash flow has changed by +$92.50 M (+42.59%)
What is Inovio Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of INO is -$27.44 M
What is the all time high quarterly FCF for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high quarterly free cash flow is $14.64 M
What is Inovio Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, INO quarterly free cash flow has changed by +$1.67 M (+5.73%)
What is Inovio Pharmaceuticals TTM free cash flow?
The current TTM FCF of INO is -$111.18 M
What is the all time high TTM FCF for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high TTM free cash flow is -$2.48 M
What is Inovio Pharmaceuticals TTM FCF year-on-year change?
Over the past year, INO TTM free cash flow has changed by +$23.74 M (+17.60%)